Compare · DFTX vs PXMD
DFTX vs PXMD
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and PaxMedica Inc. (PXMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and PXMD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX carries a market cap of $5.20B.
- DFTX has hit the wire 14 times in the past 4 weeks while PXMD has been quiet.
- DFTX has more recent analyst coverage (7 ratings vs 0 for PXMD).
- Company
- Definium Therapeutics Inc.
- PaxMedica Inc.
- Price
- $38.70+2.39%
- $0.72-3.73%
- Market cap
- $5.20B
- -
- 1M return
- -16.17%
- -
- 1Y return
- +308.71%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- News (4w)
- 14
- 0
- Recent ratings
- 7
- 0
Latest DFTX
- Chief Executive Officer Barrow Robert was granted 750,000 shares, increasing direct ownership by 50% to 2,244,640 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 125,000 shares, increasing direct ownership by 33% to 508,279 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 125,000 shares, increasing direct ownership by 46% to 397,905 units (SEC Form 4)
- Chief Commercial Officer Wiley Matthew T. was granted 125,000 shares, increasing direct ownership by 53% to 362,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 200,000 shares, increasing direct ownership by 33% to 803,699 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest PXMD
- PaxMedica Inc. filed SEC Form 8-K: Leadership Update
- PaxMedica Announces First Patent Allowance for Suramin Intranasal Formulation in the treatment of Autism Spectrum Disorder and Other Conditions
- Amendment: SEC Form SC 13G/A filed by PaxMedica Inc.
- SEC Form NT 10-Q filed by PaxMedica Inc.
- SEC Form EFFECT filed by PaxMedica Inc.
- SEC Form S-1 filed by PaxMedica Inc.
- SEC Form 10-Q filed by PaxMedica Inc.
- PaxMedica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits
- PaxMedica Secures Immediate Exercise of Warrants
- PaxMedica Reports First Patient Treated with PAX-101 for Fatal African Sleeping Sickness Infection